Cargando…

Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor

Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion inhibitor that can irreversibly conjugate to serum albumin. Previous studies demonstrated its in vivo long half-life and potent anti-HIV activity. Here, we focused to characterize its biophysical properties and eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chong, Huihui, Yao, Xue, Zhang, Chao, Cai, Lifeng, Cui, Sheng, Wang, Youchun, He, Yuxian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293837/ https://www.ncbi.nlm.nih.gov/pubmed/22403678 http://dx.doi.org/10.1371/journal.pone.0032599

Ejemplares similares

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients
por: Zhang, Hongwei, et al.
Publicado: (2016)

Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS
por: Liu, Huanxia, et al.
Publicado: (2023)

Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides
por: Mathieu, Cyrille, et al.
Publicado: (2017)

Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China
por: Nie, Jingmin, et al.
Publicado: (2021)

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19
por: He, Lin, et al.
Publicado: (2023)

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
por: Zhu, Yuanmei, et al.
Publicado: (2021)

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors
por: Geng, Xiuzhu, et al.
Publicado: (2019)

Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity
por: Wan, Chao, et al.
Publicado: (2013)

Rescue therapy with an albuvirtide-based antiretroviral regimen in an HIV-infected child with multidrug resistance and multiple opportunistic infections: a case report
por: Tang, Wei, et al.
Publicado: (2023)

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket
por: Zhang, Xiujuan, et al.
Publicado: (2018)

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
por: Yu, Danwei, et al.
Publicado: (2020)

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study
por: Su, Bin, et al.
Publicado: (2020)

Broadly neutralizing antibodies target the coronavirus fusion peptide
por: Dacon, Cherrelle, et al.
Publicado: (2022)

Broadly neutralizing antibodies target the coronavirus fusion peptide
por: Dacon, Cherrelle, et al.
Publicado: (2022)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques
por: Chong, Huihui, et al.
Publicado: (2019)

Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies
por: Yuan, Meng, et al.
Publicado: (2019)

Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK
por: Chong, Huihui, et al.
Publicado: (2014)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

5.14 The Biophysics of Membrane Fusion
por: Collins, R.N., et al.
Publicado: (2012)

Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action
por: Wang, Chen, et al.
Publicado: (2019)

Biophysical Properties and Antiviral Activities of Measles Fusion Protein Derived Peptide Conjugated with 25-Hydroxycholesterol
por: Gomes, Bárbara, et al.
Publicado: (2017)

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
por: Zhu, Yuanmei, et al.
Publicado: (2020)

Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy
por: Chen, Yue, et al.
Publicado: (2021)

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41
por: Yan, Hongxia, et al.
Publicado: (2022)

Membrane Active Peptides and Their Biophysical Characterization
por: Avci, Fatma Gizem, et al.
Publicado: (2018)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)

Morphology, Biophysical Properties and Protein-Mediated Fusion of Archaeosomes
por: Šuštar, Vid, et al.
Publicado: (2012)

In and Out — Biochemical and Biophysical Mechanisms of Viral Fusion and Assembly
por: Santos, Nuno C.
Publicado: (2010)

The Biological and Biophysical Properties of the Spider Peptide Gomesin
por: Tanner, John D., et al.
Publicado: (2018)

Biophysical characterization of HRC peptide analogs interaction with heptad repeat regions of the SARS-coronavirus Spike fusion protein core
por: Yan, Zhe, et al.
Publicado: (2006)

Analysis of biophysical and functional consequences of tropomyosin–fluorescent protein fusions
por: Brooker, Holly R., et al.
Publicado: (2016)

Biochemical and biophysical characterization of the transmissible gastroenteritis coronavirus fusion core
por: Ma, Guangpeng, et al.
Publicado: (2005)

Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study
por: Chen, Liyu, et al.
Publicado: (2022)

Human Claudin-Derived Peptides Block the Membrane Fusion Process of Zika Virus and Are Broad Flavivirus Inhibitors
por: Zoladek, Jim, et al.
Publicado: (2022)

Peptide and Peptide-Dependent Motions in MHC Proteins: Immunological Implications and Biophysical Underpinnings
por: Ayres, Cory M., et al.
Publicado: (2017)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Progress in Biophysics and Biophysical Chemistry
Publicado: (1951)

Progress in Biophysics and Biophysical Chemistry
por: Hutchinson, Franklin
Publicado: (1954)

Progress in Biophysics and Biophysical Chemistry
por: Hutchinson, Franklin
Publicado: (1953)

Cannot write session to /tmp/vufind_sessions/sess_apr797ivgn7p9m4nkj74e1a7mk